Core Viewpoint - The stock of Innovent Biologics-B (02591) rose over 3%, reaching HKD 32, following the announcement that its innovative drug, Icosapent Ethyl (brand name: Yinuo Qing®), has been included in the 2025 National Medical Insurance Drug List in China, marking a significant step towards making diabetes treatment more accessible [1]. Group 1: Company Developments - Innovent Biologics' Icosapent Ethyl is the first long-acting human GLP-1 receptor agonist (GLP-1RA) developed in China, aimed at controlling blood sugar levels in adult patients with type 2 diabetes [1]. - The drug will officially be implemented in the national insurance scheme starting January 1, 2026, enhancing its market accessibility [1]. Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list aligns with the "Healthy China 2030" initiative, which aims to advance diabetes prevention and treatment [1]. - The National Guidelines for Diabetes Prevention and Management (2025) classify Icosapent Ethyl as a GLP-1RA injectable medication, providing a policy framework for its use in primary healthcare settings [1]. - The guidelines highlight GLP-1RA as a crucial treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1].
港股异动 银诺医药-B(02591)盘中涨超3% 依苏帕格鲁肽ɑ获国家基层糖尿病防治指南推荐